Sandoz International GmbH
www.sandoz.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Sandoz International GmbH
Sandoz ‘Surfs The Biosimilars Wave’ Despite US Natalizumab Delay
With Sandoz delivering first-quarter growth thanks to its booming biosimilars business – and despite flat sales of small-molecule generics that suffered from a downturn in North America – the company is “well on track to surf the biosimilars wave,” according to one analyst. However, Sandoz did report a delay to progress with its natalizumab biosimilar in the US that will push back launch.
Lupin Enters Canadian Biosimilars Market With Etanercept
Lupin has pushed into the Canadian biosimilars market with the launch of its Rymti rival to Amgen’s Enbrel. The launch is taking place via Lupin’s local partner Sandoz.
Sandoz Settlement Sets Date For US Denosumab Entry
Sandoz has secured a launch date for its newly-approved US denosumab biosimilars, settling patent litigation with Prolia/Xgeva originator Amgen.
Stick, Twist Or Split? Generics Industry’s Big Three Place Their Bets
With Teva and Viatris recently under new management and Sandoz having last year split from former parent company Novartis, the three off-patent industry leaders are adopting different strategies for how they balance their generics and biosimilars interests with more innovative ventures. Generics Bulletin takes a look at the bigger picture.
Company Information
- Industry
-
Pharmaceuticals
- Generic Drugs
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice